Researchers report engineered nanovesicles that target METTL3, the m6A writer, to curb neuroinflammation in both cell and animal models. The work, published in Nature Communications, describes a delivery approach that modulates methylation biology inside the nervous system to reduce inflammatory activation. METTL3 is an RNA methyltransferase that controls N6-methyladenosine (m6A) marks; in neuroinflammatory settings, altering m6A regulation can change downstream gene expression programs. The team used engineered vesicles to deliver or engage the target and observed reductions in inflammatory readouts in vitro and in vivo. If the signal holds in further preclinical programs, METTL3-directed nanovesicles may expand the therapeutic toolbox for neurodegenerative disease and CNS injury, where inflammation frequently accelerates tissue damage and dysfunction.